Patent intelligence · US
US 12219327
Substituted isoindolines as PI3K-alpha inhibitors
Substituted isoindolines as PI3K-alpha inhibitors
Patent details — US 12219327
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 4, 2025
- Expiration
- Jan 30, 2045
- Applicant
- Relay Therapeutics, Inc.
- Claims
- 6
- CPC classes
- A61K, A61K31/4035, A61K31/404, A61K31/4155
Quick answer
US 12219327 (Substituted isoindolines as PI3K-alpha inhibitors) is held by Relay Therapeutics, Inc.. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Relay Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/4035, A61K31/404, A61K31/4155, A61K31/416, A61K31/428
More from Relay Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12331056
SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 12152034
FGFR inhibitors and methods of making and using the same
granted -
US 12138263
Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 12084447
SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 11890281
SHP2 phosphatase inhibitors and methods of making and using the same
granted -
US 11780845
FGFR inhibitors and methods of use thereof
granted -
US 11701354
Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
granted
Frequently asked questions
What is US patent 12219327?
US 12219327 (Substituted isoindolines as PI3K-alpha inhibitors) is held by Relay Therapeutics, Inc.. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12219327?
Relay Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12219327 expire?
Our index shows an expiration date of Jan 30, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.